Here are the 10-K annual reports from Erasca, Inc. (ERAS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ERAS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERAS filings page.
Erasca, Inc. files its annual report describing a focused strategy to develop precision oncology drugs that shut down the RAS/MAPK pathway in cancer. The company highlights two clinical-stage programs, ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), plus discovery-stage EGFR antibody ERAS-12.
Early Phase 1 data for ERAS-0015 show partial responses at low doses with favorable safety and linear pharmacokinetics. Erasca exercised its option to expand territorial rights for ERAS-0015 globally (including mainland China) under its Joyo license and is preparing multiple monotherapy and combination readouts in 2026–2027.
The company streamlined its portfolio by terminating several legacy programs and license agreements to concentrate resources on its RAS franchise and EGFR antibody platform. As of June 30, 2025, non-affiliate common stock held an aggregate market value of $316.4 million, and common shares outstanding totaled 310,799,547 as of March 5, 2026.